

## Supplementary Data

SUPPLEMENTARY TABLE S1. NUMBER AND PERCENTAGE  
OF WOMEN WITH TREATMENT-RELATED ADVERSE  
EVENTS WITH OSPEMIFENE 60 MG

<i>Preferred term,<sup>a</sup> n (%)</i>	<i>Placebo (n=958)</i>	<i>Ospemifene 60 mg (n=1242)</i>
Any treatment-related AE	157 (16.4)	378 (30.4)
Hot flush	25 (2.6)	93 (7.5)
Vaginal discharge	3 (0.3)	47 (3.8)
Muscle spasms	9 (0.9)	40 (3.2)
Headache	23 (2.4)	30 (2.4)
Hyperhidrosis	6 (0.6)	20 (1.6)
Genital discharge	1 (0.1)	16 (1.3)

<sup>a</sup>Subjects with >1 treatment-related AE that coded for the same preferred term were counted once for that preferred term.  
AE, adverse event.